1. Pink Sheet
  2. >>Geography
  3. >>North America

FDA To ANDA Sponsors: Don't Forget Quality When Rushing For 10-Month Review Goal

 
• By Derrick Gingery

Agency discusses potential bolus of applications in new fiscal year.

FDA warned again that application quality will be important as it prepares for a potential bolus of ANDAs that could arrive in October when review goals are enhanced again.

The beginning of fiscal year 2017 will mark the zenith of the first cycle of the generic drug user fee program

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

Most Favored Nation Pricing Policy Floated In Medicaid, Coming Back To Medicare?

 
• By Cathy Kelly

President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention.

US FDA Advisory Committee Misperceptions Abound … At HHS

 
• By Michael McCaughan

HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.